

## Genetic Engineering to Induce Fetal-Like Hematopoietic Stem Cells

Barış Ulum, Stefan A. Muljo\*

*Integrative Immunobiology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA*

### ABSTRACT

Bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) is an archetype of cellular therapy. However, to date BMT still suffers from several complications. Recent technological advances have encouraged us to think about an alternative to traditional BMT. Specifically, we propose in utero HSCT (IUHSCT). For this purpose, we suggest that induced fetal-like hematopoietic stem cells (ifHSCs) might be suitable for IUHSCT, and should be seriously evaluated.

**Keywords:** Regenerative Medicine; Precision Medicine; Cellular Engineering; Cellular Therapy; Prenatal Therapy; Hematopoietic Stem Cells; RNA-binding Proteins

### DESCRIPTION

Bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) is an archetype of cellular therapy. Hematopoietic stem cells (HSCs) that reside in the bone marrow are responsible for regenerating hematopoiesis and the immune system upon BMT. Dr. E. Donnall Thomas was the first to perform BMT in a human patient [1,2], and consequently, won the Nobel Prize in Physiology or Medicine in 1990 for his pioneering work. BMT is recognized to cure many forms of human immunodeficiencies and hematological disorders. From 1957 to 2016, over 1.3 million BMTs have been performed worldwide [3]. However, to date BMT still suffers from several complications including but not limited to the following:

- **Pre-conditioning (myeloablation) prior to HSCT facilitates engraftment of transplanted HSCs in the bone marrow niche.** Usually, these regimens are very toxic, leave patients immunocompromised until the immune system is regenerated and can cause sterility and other developmental problems in pediatric patients [4,5]. Furthermore, there are some radio-sensitive primary immunodeficiencies that have contraindications for DNA-damaging pre-conditioning regimens such as alkylating agents (eg. busulfan) or ionizing radiation [6]. Thus, would it not be ideal if there was an alternative procedure that did not require myeloablation?

- **Human leukocyte antigen (HLA) matching is critical** [7]. However, it can be challenging to find a genetically related or similar donor to supply histocompatible bone marrow-derived cells [8]. Thus, would it not be ideal if there was an alternative procedure that instead utilized a universal HSC?
- **Graft-versus-host disease (GVHD) is a common sequela.** It can cause lethality when the donor cells mount an immune reaction against the recipient patient's tissues and organs [9]. Thus, would it not be ideal if there was an alternative procedure that did not have an incidence of GVHD?
- **Incomplete reconstitution following BMT is a problem that is not widely investigated.** When performed without myeloablation, Vély et al. reported that innate lymphoid cells are not regenerated [10]. Furthermore, we argue that BMT is not natural because principally it only reconstitutes the adult waves of hematopoiesis and completely bypasses the initial waves of development that occur prior to birth. Therefore, it is likely that other subsets of cells are not regenerated following this standard of care. For instance, in mice, a special subset of innate-like B cells called B-1 that are generated early in life are not reconstituted after BMT [11, 12]. Although this has not yet been investigated in humans, we predict that the same issue would occur in patients post-BMT. Thus, would it not be ideal if there was an alternative procedure that mimicked nature more closely?

**Correspondence to:** Dr. Stefan A. Muljo, Integrative Immunobiology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA, E-mail: stefan.muljo@nih.gov


**Received:** July 15, 2020; **Accepted:** July 29, 2020; **Published:** August 05, 2020

**Citation:** Ulum B, Muljo SA (2020) Genetic Engineering to Induce Fetal-Like Hematopoietic Stem Cells. *Gene Technol.* 9:154. DOI: 10.35248/2329-6682.20.9.154.

**Copyright:** © 2020 Ulum B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

These fundamental issues and recent technological advances have encouraged us to think about an alternative to traditional BMT. In the age of Precision Medicine, it is possible to diagnose many inborn errors of the hematopoietic or immune system prenatally [13-15]. Ideally, early diagnosis would be coupled with early treatment. It is not uncommon that such patients would need to wait years prior to receiving BMT, and in the meanwhile, they may suffer long term and/or life-threatening effects of their disease. Therefore, it is important to consider in utero HSC transplantation (IUHST, Figure 1A) for these cases [16]. Indeed, in sheep and monkeys, IUHSTs have been demonstrated to work without the need for pre-conditioning, HLA matching or immunosuppression since GVHD was not observed [17, 18]. In these pioneering studies, investigators used HSCs derived from fetal liver (FL) as opposed to stem cells from adult donors which are commonly used for BMT.

In some countries, however, it is impossible to procure human FLs [19]. Research from our laboratory demonstrated that in principle it is possible to reprogram adult HSCs into a fetal-like state. In 2012, we identified the RNA-binding protein (RBP) Lin28b (Figure 1B) as one such factor capable of rejuvenating adult mouse HSCs and lymphoid progenitors [12]. Recently, we identified Igf2bp3 (Figure 1C), another RBP, as a second factor that determines the fetal hematopoietic fate [11]. Furthermore, we found evidence that Lin28b and Igf2bp3 cooperate to enact the fetal hematopoietic program [11]. Thus, we highlight the possibility of generating induced fetal-like HSCs (ifHSCs) which might be a suitable alternative to bona fide FL-derived HSCs (Figure 1A). Accordingly, we propose that ifHSCs should be seriously evaluated for IUHST in the future raising the hope that one day otherwise sick babies could be born cured.



**Figure 1:** (A) A Regenerative Precision Medicine strategy aims to couple prenatal genetic diagnosis of inborn errors of hematopoiesis or immunity with IUHST. As an alternative to FL-derived HSCs, adult bone marrow-derived HSCs will undergo LIN28B and/or IGF2BP3-mediated reprogramming prior to IUHST. Reprogramming could be accomplished using approved viral vectors for gene therapy or by transfection of synthetic modified mRNAs encoding LIN28B and/or IGF2BP3. (B) Schematic depicts known domain structure of human LIN28A and LIN28B RNA-binding proteins. LIN28A is 209 amino acids (aa) long including the following domains: cold shock domain (CSD, aa 39 – 112), two CCHC-type Zinc (Zn) fingers (aa 137–154, and 159–176). LIN28B is 250 aa long including the following domains: CSD (aa 29–102), two CCHC-type Zn fingers (aa 127–144, and 149–166). Annotations are based on <https://www.uniprot.org/uniprot/Q9H9Z2> and <https://www.uniprot.org/uniprot/Q6ZN17> respectively. (C) Schematic depicts known domain structure of human IGF2BP1, IGF2BP2 and IGF2BP3 RNA-binding proteins. IGF2BP1 is 577 aa long including the following domains: two RNA-recognition motifs (RRM, aa 2–75, and 81–156), and four K homology domains (KH, aa 195–260, 276–343, 405–470, and 487–553). IGF2BP2 is 599 aa long including the following domains: two RRM (aa 3–76, and 82–157), and four KH domains (aa 193–258, 274–341, 427–492, and 509–575). IGF2BP3 is 571 aa long including the following domains: two RRM (aa 2–75, and 81–156), and four KH domains (aa 195–260, 276–343, 405–470, and 487–553). Annotations are based on <https://www.uniprot.org/uniprot/Q9NZI8>, <https://www.uniprot.org/uniprot/Q9Y6M1> and <https://www.uniprot.org/uniprot/O00425> respectively.

## ACKNOWLEDGEMENTS

We thank Rose Perry (Research Technologies Branch, NIAID) for preparing Figure 1; Chrysi Kanellopoulou (Incyte Research Institute) and Xiuhuai Liu (NIAID) for comments and suggestions. This research was supported by the NIH Intramural Research Program of NIAID, NIH (ZIA AI001185).

## REFERENCES

1. Thomas ED, Lochte HL, Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. *J Clin Invest.* 1959;38(10):1709-1716.
2. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *N Engl J Med.* 1957;257(11):491-496.
3. Niederwieser D, Baldomero H, Atsuta Y, Aljurf M, Seber A, Greinix HT, et al. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT). *Blood.* 2019;134(S1):2035.
4. Locatelli F, Giorgiani G, Pession A, Bozzola M. Late effects in children after bone marrow transplantation: a review. *Haematologica.* 1993;78(5):319-328.
5. Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. *Pediatr Res.* 2012;71(4):439-444.
6. Cowan MJ, Gennery AR. Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation-what to do? *J Allergy Clin Immunol.* 2015;136(5):1178-1185.
7. Eyrich M, Schulze H. HLA Matching in pediatric stem cell transplantation. *Transfus Med Hemother.* 2019;46(5):348-355.
8. Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, et al. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". *Bone Marrow Transplant.* 2019;54(8):1179-1188.
9. Ferrara JL, Deeg HJ. Graft-versus-host disease. *N Engl J Med.* 1991;324:667-674.
10. Vely F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M, et al. Evidence of innate lymphoid cell redundancy in humans. *Nat Immunol.* 2016;17(11):1291-1299.
11. Wang S, Chim B, Su Y, Khil P, Wong M, Wang X, et al. Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3. *Genes Dev.* 2019;33(15-16):1048-1068.
12. Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. *Science.* 2012;335(6073):1195-1200.
13. Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive prenatal genetic testing: current and emerging ethical, legal, and social issues. *Annu Rev Genomics Hum Genet.* 2015;16:369-398.
14. Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, et al. Use of genetic testing for primary immunodeficiency patients. *J Clin Immunol.* 2018;38(3):320-329.
15. Daniel Y, Campen JV, Silcock L, Yau M, Ahn JW, Ogilvie C, et al. Non-invasive prenatal diagnosis (NIPD) of sickle-cell disease by massively parallel sequencing of cell-free fetal DNA in maternal serum. *Blood.* 2019;134(S1):2085-2085.
16. Almeida-Porada G, Atala A, Porada CD. In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application. *Mol Ther Methods Clin Dev.* 2016;5:16020.
17. Flake AW, Harrison MR, Adzick NS, Zanjani ED. Transplantation of fetal hematopoietic stem cells in utero: the creation of hematopoietic chimeras. *Science.* 1986;233(4765):776-778.
18. Harrison MR, Slotnick RN, Crombleholme TM, Golbus MS, Tarantal AF, Zanjani ED. In-utero transplantation of fetal liver haemopoietic stem cells in monkeys. *Lancet.* 1989;2(8677):1425-1427.
19. Wadman M. NIH says cancer study also hit by fetal tissue ban. *Science.* 2018.